The State of Remote Patient Monitoring for Chronic Disease Management in the United States.

Publication date: Jun 26, 2025

Remote patient monitoring (RPM) increased exponentially during the COVID-19 pandemic. RPM programs commonly incorporate tools to capture and transmit health-relevant data from the home to the clinical space to augment the clinical decision-making process of health care providers. Given the potential to improve patient health outcomes, health care systems around the world are actively engaged in fashioning, implementing, and exploring the outcomes of various RPM program models. However, new challenges to health care systems include increasing RPM program enrollment, optimizing condition-specific RPM programs to best address the needs of specific patient groups, integrating new RPM-derived data streams into existing IT infrastructure, overcoming limited availability of desired remote monitoring technologies, and quantifying the health outcomes produced by RPM use. Herein, we identify stakeholders for RPM in the United States, summarize the landscape of RPM tools available for chronic disease management, discuss the current regulatory environment, delve into the benefits and challenges of integrating these tools into clinical practice, summarize aspects of coverage and reimbursement, and examine the knowledge and policy gaps regarding sustained use of RPM in clinical practice, along with associated opportunities.

Open Access PDF

Concepts Keywords
Covid Chronic Disease
Home chronic disease
Increased chronic disease management
Pandemic COVID-19
Patient Disease Management
health information systems
Humans
Monitoring, Physiologic
Pandemics
reimbursement mechanisms
Remote Patient Monitoring
remote patient monitoring
SARS-CoV-2
Telemedicine
telemedicine
United States

Semantics

Type Source Name
disease MESH Chronic Disease
disease MESH COVID-19 pandemic
disease IDO process
drug DRUGBANK Montelukast
disease MESH emergency
disease MESH diabetes mellitus
disease MESH hyperlipidemia
drug DRUGBANK Metformin
disease MESH uncertainty
disease MESH low socioeconomic status
disease IDO blood
drug DRUGBANK Dextrose unspecified form
disease MESH Heart failure
disease MESH High risk pregnancy
disease MESH Arrhythmia
disease MESH Seizure
disease MESH Asthma
pathway KEGG Asthma
disease MESH pneumonia
disease MESH cirrhosis
disease MESH stroke
drug DRUGBANK Etoperidone
disease MESH hypertension
disease MESH kidney disease
disease MESH liver disease
disease IDO quality
disease MESH Allergy
disease IDO symptom
disease MESH privacy
disease MESH lifestyle
disease IDO intervention
pathway REACTOME Reproduction

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *